Treatment of Generalized Pustular Psoriasis with Bimekizumab
Main Article Content
Keywords
generalized pustular psoriasis, bimekizumab, infliximab, plaque psoriasis, psoriatic arthritis
Abstract
Generalized pustular psoriasis (GPP) is a rare but serious subtype of pustular psoriasis. In the United States, the IL-36 inhibitor spesolimab is the only medication currently approved for GPP. We describe the longitudinal treatment of a patient with concomitant GPP, plaque psoriasis, and psoriatic arthritis. After almost a decade of recalcitrant disease and difficulty managing cardiovascular concerns, the patient was successfully treated with bimekizumab, a novel biologic targeting IL-17A/F. To our knowledge, this represents the first case of concomitant GPP and plaque psoriasis treated with this immunomodulator, offering additional treatment options for patients with this challenging disease.
References
2. Ericson O, Löfvendahl S, Norlin JM, Gyllensvärd H, Schmitt-Egenolf M. Mortality in generalized pustular psoriasis: A population-based national register study. J Am Acad Dermatol. 2023;89(3):616-619. doi:10.1016/j.jaad.2023.04.066
3. Marrakchi S, Puig L. Pathophysiology of Generalized Pustular Psoriasis. Am J Clin Dermatol. 2022;23(1):13-19. doi:10.1007/s40257-021-00655-y
4. Krueger J, Puig L, Thaçi D. Treatment Options and Goals for Patients with Generalized Pustular Psoriasis. Am J Clin Dermatol. 2022;23(1):51-64. doi:10.1007/s40257-021-00658-9
5. Twelves S, Mostafa A, Dand N, et al. Clinical and genetic differences between pustular psoriasis subtypes. J Allergy Clin Immunol. 2019;143(3):1021-1026. doi:10.1016/j.jaci.2018.06.038
6. Tada Y, Guan J, Iwasaki R, Morita A. Treatment patterns and drug survival for generalized pustular psoriasis: A patient journey study using a Japanese claims database. J Dermatol. 2024;51(3):391-402. doi:10.1111/1346-8138.17097
7. Elewski BE, Lebwohl MG, Anadkat MJ, et al. Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study. J Am Acad Dermatol. 2023;89(1):36-44. doi:10.1016/j.jaad.2023.02.040
8. Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus Secukinumab in Plaque Psoriasis. N Engl J Med. 2021;385(2):142-152. doi:10.1056/NEJMoa2102383
9. Hagino T, Saeki H, Kanda N. Two cases of generalized pustular psoriasis successfully treated with bimekizumab. J Dermatol. 2023;50(10):e357-e358. doi:10.1111/1346-8138.16866
10. Shukuin R, Koizumi H, Ebata A, et al. Successful combination therapy of bimekizumab and granulocyte monocyte adsorption apheresis for generalized pustular psoriasis complicated with microscopic polyangiitis. J Dermatol. 2023;50(6):e181-e182. doi:10.1111/1346-8138.16707
11. Passeron T, Perrot JL, Jullien D, et al. Treatment of Severe Palmoplantar Pustular Psoriasis With Bimekizumab. JAMA Dermatol. 2024;160(2):199-203. doi:10.1001/jamadermatol.2023.5051
12. Yoshikawa T, Takeichi T, Fukaura R, Ikeya S, Akiyama M. Generalized acrodermatitis continua of Hallopeau with an IL36RN variant successfully treated with bimekizumab. J Dermatol. n/a(n/a). doi:10.1111/1346-8138.17370